amgen inc nhic refuses to cover off label use of aranesp a second company that administers medicare plans in several states decided not to pay for the use of amgen inc s aranesp anti anemia drug in certain cancer patients amid safety concerns nhic a unit of electronic data systems corp will no longer pay for aranesps use in "anemia of cancer" patients or anemia possibly caused by cancer eds said this is an off label or unapproved use of the drug the approved use is in anemia that is induced by chemotherapy nhic joins another medicare carrier noridian administrative services llc in declining to cover aranesp in anemia of cancer following recent disclosures of clinical trials in which aranesp was associated with increased risk of death or tumor growth in certain cancer patients the company is in talks with european regulators to update product labels for its anti anemia drugs 
